Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer Center ( Site 1904) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Liga Norte Riograndense Contra o Cancer ( Site 1301) | Natal, Rio Grande do Norte, Brazil | Recruiting |
| Hospital Nossa Senhora da Conceicao ( Site 1300) | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1302) | São Paulo, Brazil | Recruiting |
| Clínica Puerto Montt ( Site 1406) | Port Montt, Los Lagos Region, Chile | Recruiting |
| FALP ( Site 1400) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Centro de Oncología de Precisión ( Site 1402) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Clínica UC San Carlos de Apoquindo ( Site 1403) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Bradfordhill ( Site 1401) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Bradford Hill Norte ( Site 1405) | Antofagasta, Chile | Recruiting |
| The Second Affiliated Hospital of Anhui Medical University ( Site 9511) | Hefei, Anhui, China | Recruiting |
| Beijing Cancer Hospital ( Site 9500) | Beijing, Beijing Municipality, China | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780111